Sign in
CompletedPhase 2

Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare

Key facts

Who runs it
Changchun GeneScience Pharmaceutical Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
106 people enrolled
Started
21 Jul 2023
Ended
28 Feb 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Genakumab for injection
  • Colchicine
Record updated
8 November 2024

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Other criteria

  • Male or female, 18 years ≤ age ≤ 75 years
  • BMI ≤ 40kg/m2
  • Meeting ACR 2015 preliminary criteria for the classification of acute arthritis of primary gout
  • Start of acute gout flare within 3 days prior to enrolled
  • History of ≥2 gout flare within 12 months prior to study start
  • Baseline pain intensity ≥ 50mm on the 0-100mm visual analog scale(VAS)

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the safety and efficacy of Genakumab for Injection in patients with gout flare as a first line therapy

The 2 groups in the trial

  • Genacumab groupTreatment being tested

    Genakumab 200mg single injection

    Treatment: Genakumab for injection

  • cholchicine groupExisting treatment, for comparison

    Colchicine 0.5mg qd po.for 12 weeks

    Treatment: Colchicine

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Open Lable, Multi-center, Active Competitor Phase 2 Study for Evaluating Efficacy and Safety of Genakumab for Injection as First Line Therapy in Patients With Gout Flare
Publications
Record updated
8 November 2024